Performance History
| Key Stats | |
|---|---|
| Open | $47.66 |
| Prev. Close | $47.10 |
| EPS | -1.2 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $2.44B |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 46.95 | 47.75 |
| 52 Week Range | 5.65 | 65.60 |
| Ratios | |
|---|---|
| P/B Ratio | 7.90 |
| Revenue | $8.08M |
| Operating M. % | -1,610.30% |
| Earnings | $0.00 |
| Earnings Growth % | 7.56% |
| EBITDA Margin % | -876.22% |
| ROE % | -11.50% |
| EPS | -1.2 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Janux Therapeutics (JANX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David Alan Campbell Ph.D.
- Headquarters
- La Jolla
- Employees
- 67
- Exchange
- NASDAQ
Keep an eye on Janux Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Janux Therapeutics's (JANX) price per share?
The current price per share for Janux Therapeutics (JANX) is $47.53. The stock has seen a price change of $0.43 recently, indicating a 0.91% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Janux Therapeutics (JANX)?
For Janux Therapeutics (JANX), the 52-week high is $65.6, which is 38.02% from the current price. The 52-week low is $5.65, the current price is 741.24% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Janux Therapeutics (JANX) a growth stock?
Janux Therapeutics (JANX) has shown an average price growth of 0.41% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Janux Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Janux Therapeutics (JANX) stock price performance year to date (YTD)?
As of the latest data, Janux Therapeutics (JANX) has a year-to-date price change of 331.31%. Over the past month, the stock has experienced a price change of -2.38%. Over the last three months, the change has been 377.21%. Over the past six months, the figure is 425.19%.
Is Janux Therapeutics (JANX) a profitable company?
Janux Therapeutics (JANX) has a net income of -$58.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.81% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.61K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.08M, although specific revenue growth data is currently not available. The gross profit is $6.13M. Operating income is noted at -$72.98M. Furthermore, the EBITDA is -$70.82M.
What is the market capitalization of Janux Therapeutics (JANX)?
Janux Therapeutics (JANX) has a market capitalization of $2.44B. The average daily trading volume is 847.35K, indicating the stock's liquidity and investor engagement.
News
Bitcoin Addresses with Balances Over $1 Million Have Reached an All-time High of Over 112,000
UK’s AI Safety Institute Expands Global Footprint with New San Francisco Office
Global Cybercrime Cost is Growing 12x Faster than Total Cybersecurity Spending
Indian IT Titans Struggle as AI Revolution Transforms Global Tech Landscape
Five Best-Performing Healthcare Companies Added Over $14 Billion to Their Stock Values Year-to-Date
Apple’s iPad Accounted for Nearly 2 in Every 5 Tablets Shipped Globally in 2023
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.